Affect Therapeutics

Affect Therapeutics is an addiction-treatment facility located in Jacksonville, FL. The facility's programming is outpatient (IOP, MAT), not residential. What follows is an orientation — not a review — to the practical questions worth asking before admission.

Care levels at Affect Therapeutics

The care-level question matters because what a facility offers is what it can realistically treat well. Affect Therapeutics is an outpatient-focused program (IOP, MAT) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. Before admission, an independent clinical assessment (from a primary-care doctor, licensed substance-use counselor, or addiction-medicine physician) can confirm whether Affect Therapeutics's offerings match the clinical need.

Insurance and payment

Affect Therapeutics accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. What tends to produce post-admission financial surprise is not the facility being out of network — it is the verbal assurance that did not make it into writing. Ask for the written VOB before admission, save the email, and the rest of the financial conversation becomes a lot simpler.

Before you call

Before admission to Affect Therapeutics, three questions consistently produce the most useful information: (1) which ASAM level of care are you treating me at, and what is the clinical rationale; (2) can you send me a written Verification of Benefits for my specific insurance plan; (3) what is your policy on medication-assisted treatment for opioid use disorder — specifically, do you continue patients on buprenorphine or methadone during residential programming. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.